What to know about the next big Alzheimer's readout; how real-world data can help expedite drug approvals

Taking stock of the drug industry, from the lab to the medicine chest ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

STAT+: Everything you need to know before the next big Alzheimer's readout By Damian Garde and Adam Feuerstein National Institute on Aging, NIH By the end of September, the world will learn whether lecanemab can significantly slow the cognitive decline that characterizes Alzheimer’s. Read More Opinion: Real-world data can help expedite drug approvals for serious diseases with few options By Elenee Argentinis Adobe Connecting real-world data from participants in registration trials can expedite the path to validating effectiveness and safety. Read More Opinion: Implant recipients shouldn't be left in the dark when a device maker cuts off support By Klaudia Jaźwińska Al Barry/Three Lions/Getty Images Regulators need to act fast to protect individuals who receive cutting-edge medical implants if a company stops supporting its product. Read More Sponsor content by STAT+ Open Doors: Be the exclusive sponsor of a first-of-its-kind civic collaboration Open Doors aims to bring the most creative and innovative minds in health care, technology, and business together to shine a light on the pressing issues in the health sector and what we can do to drive change. Join the conversation. What scientists know — and don't know — about how monkeypox spreads By Megan Molteni NIAID What's clear from the evidence so far is that the current epidemic is being driven overwhelmingly by skin-to-skin contact with lesions. Read More Wednesday, August 10, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser